Hodgkin lymphoma patients in first remission: Routine positron emission tomography/computerized tomography imaging is not superior to clinical follow-up for patients with no residual mass

British Journal of Haematology

Volumn 164, Issue 5, 2014, Pages 694-700

  Dann, Eldad J ^a,b,c   Berkahn, Leanne ^d,e   Mashiach, Tatiana ^f   Frumer, Michael ^c   Agur, Ariel ^g   Mcdiarmid, Bridgett ^d   Bar Shalom, Rachel ^b,c   Paltiel, Ora ^g   Goldschmidt, Neta ^g  

^a Blood Bank and Apheresis Unit   (Israel)

^b Israel Institute of Technology ^*  (Israel)

^c TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^d AUCKLAND CITY HOSPITAL   (New Zealand)

^e UNIVERSITY OF AUCKLAND   (New Zealand)

^f Quality Assurance Unit   (Israel)

^g HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

Clinical follow up; Hodgkin lymphoma; Positron emission tomography computerized tomography; Remission; Sensitivity

Indexed keywords

CLINICAL FOLLOW-UP; HODGKIN LYMPHOMA; POSITRON EMISSION TOMOGRAPHY/COMPUTERIZED TOMOGRAPHY; REMISSION; SENSITIVITY;

FEMALE; FOLLOW-UP STUDIES; HEALTH CARE COSTS; HODGKIN DISEASE; HUMANS; ISRAEL; KAPLAN-MEIER ESTIMATE; LONG-TERM CARE; MALE; MULTIMODAL IMAGING; NEOPLASM STAGING; NEOPLASM, RESIDUAL; NEW ZEALAND; POPULATION SURVEILLANCE; POSITRON-EMISSION TOMOGRAPHY; RECURRENCE; REMISSION INDUCTION; RETROSPECTIVE STUDIES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84894064180     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/bjh.12687     Document Type: Article

References (22)

1. Borchmann, P., Eichenauer, D.A. & Engert, A. (2012) State of the art in the treatment of Hodgkin lymphoma. Nature Reviews Clinical Oncology, 9, 450-459.
2. Carbone, P.P., Kaplan, H.S., Musshoff, K., Smithers, D.W. & Tubiana, M. (1971) Report of the committee on Hodgkin's disease staging classification. Cancer Research, 31, 1860-1861.
3. Cheson, B.D. (2011) Role of functional imaging in the management of lymphoma. Journal of Clinical Oncology, 29, 1844-1854.
4. Cheson, B.D., Pfistner, B., Juweid, M.E., Gascoyne, R.D., Specht, L., Horning, S.J., Coiffier, B., Fisher, R.I., Hagenbeek, A., Zucca, E., Rosen, S.T., Stroobants, S., Lister, T.A., Hoppe, R.T., Dreyling, M., Tobinai, K., Vose, J.M., Connors, J.M., Federico, M. & Diehl, V.; International Harmonization Project on Lymphoma (2007) Revised response criteria for malignant lymphoma. Journal of Clinical Oncology, 25, 579-586.
5. Crocchiolo, R., Fallanca, F., Giovacchini, G., Ferreri, A.J., Assanelli, A., Verona, C., Pescarollo, A., Bregni, M., Ponzoni, M., Gianolli, L., Fazio, F. & Ciceri, F. (2009) Role of 18FDG-PET/CT in detecting relapse during follow-up of patients with Hodgkin's lymphoma. Annals of Hematology, 88, 1229-1236.
6. Dann, E.J., Bairey, O., Bar-Shalom, R., Izak, M., Korenberg, A., Akria, L., Attias, D., Filanovsky, K., Abdach, L., Goldschmidt, R., Epelbaum, R., Rowe, J.M., Ben Yehuda, D., Shpilberg, O. & Paltiel, O.B. (2010) Tailored therapy in Hodgkin lymphoma, based on predefined risk factors and early interim PET/CT, can lead to modification and safe reduction in therapy: results of 134 patients on the Israel national Hodgkin study. Blood, 116, 2809.
7. Diehl, V., Franklin, J., Pfreundschuh, M., Lathan, B., Paulus, U., Hasenclever, D., Tesch, H., Herrmann, R., Dörken, B., Müller-Hermelink, H.K., Dühmke, E. & Loeffler, M.; German Hodgkin's Lymphoma Study Group (2003) Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. New England Journal of Medicine, 348, 2386-2395.
8. Dryver, E.T., Jernström, H., Tompkins, K., Buckstein, R. & Imrie, K.R. (2003) Follow-up of patients with Hodgkin's disease following curative treatment: the routine CT scan is of little value. British Journal of Cancer, 89, 482-486.
9. Eich, H.T., Diehl, V., Görgen, H., Pabst, T., Markova, J., Debus, J., Ho, A., Dörken, B., Rank, A., Grosu, A.L., Wiegel, T., Karstens, J.H., Greil, R., Willich, N., Schmidberger, H., Döhner, H., Borchmann, P., Müller-Hermelink, H.K., Müller, R.P. & Engert, A. (2010) Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. Journal of Clinical Oncology, 28, 4199-4206.
10. Eichenauer, D.A., Engert, A. & Dreyling, M.; ESMO Guidelines Working Group (2011) Hodgkin's lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 22(Suppl. 6), vi55-vi58.
11. El-Galaly, T.C., Mylam, K.J., Brown, P., Specht, L., Christiansen, I., Munksgaard, L., Johnsen, H.E., Loft, A., Bukh, A., Iyer, V., Nielsen, A.L. & Hutchings, M. (2012) Positron emission tomography/computed tomography surveillance in patients with Hodgkin lymphoma in first remission has a low positive predictive value and high costs. Haematologica, 97, 931-936.
12. Fazel, R., Krumholz, H.M., Wang, Y., Ross, J.S., Chen, J., Ting, H.H., Shah, N.D., Nasir, K., Einstein, A.J. & Nallamothu, B.K. (2009) Exposure to low-dose ionizing radiation from medical imaging procedures. New England Journal of Medicine, 361, 849-857.
13. Goldschmidt, N., Or, O., Klein, M., Savitsky, B. & Paltiel, O. (2011) The role of routine imaging procedures in the detection of relapse of patients with Hodgkin lymphoma and aggressive non-Hodgkin lymphoma. Annals of Hematology, 90, 165-171.
14. Hasenclever, D. & Diehl, V. (1998) A prognostic score for advanced Hodgkin's disease. International prognostic factors project on advanced Hodgkin's disease. New England Journal of Medicine, 339, 1506-1514.
15. Hutchings, M., Loft, A., Hansen, M., Pedersen, L.M., Buhl, T., Jurlander, J., Buus, S., Keiding, S., D'Amore, F., Boesen, A.M., Berthelsen, A.K. & Specht, L. (2006) FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood, 107, 52-59.
16. Kobe, C., Dietlein, M., Franklin, J., Markova, J., Lohri, A., Amthauer, H., Klutmann, S., Knapp, W.H., Zijlstra, J.M., Bockisch, A., Weckesser, M., Lorenz, R., Schreckenberger, M., Bares, R., Eich, H.T., Mueller, R.P., Fuchs, M., Borchmann, P., Schicha, H., Diehl, V. & Engert, A. (2008) Positron emission tomography has a high negative predictive value for progression or early relapse for patients with residual disease after first-line chemotherapy in advanced-stage Hodgkin lymphoma. Blood, 112, 3989-3994.
17. Lee, A.I., Zuckerman, D.S., Van den Abbeele, A.D., Aquino, S.L., Crowley, D., Toomey, C., Lacasce, A.S., Feng, Y., Neuberg, D.S. & Hochberg, E.P. (2010) Surveillance imaging of Hodgkin lymphoma patients in first remission: a clinical and economic analysis. Cancer, 116, 3835-3842.
18. Mikhaeel, N.G., Hutchings, M., Fields, P.A., O'Doherty, M.J. & Timothy, A.R. (2005) FDG-PET after two to three cycles of chemotherapy predicts progression-free and overall survival in high-grade non-Hodgkin lymphoma. Annals of Oncology, 16, 1514-1523.
19. Petrausch, U., Samaras, P., Veit-Haibach, P., Tschopp, A., Soyka, J.D., Knuth, A., Hany, T.F., Mischo, A., Renner, C. & Schaefer, N.G. (2010) Hodgkin's lymphoma in remission after first-line therapy: which patients need FDG-PET/CT for follow-up? Annals of Oncology, 21, 1053-1057.
20. Radford, J.A., Eardley, A., Woodman, C. & Crowther, D. (1997) Follow up policy after treatment for Hodgkin's disease: too many clinic visits and routine tests? A review of hospital records. BMJ, 314, 343-346.
21. Straus, D.J., Portlock, C.S., Qin, J., Myers, J., Zelenetz, A.D., Moskowitz, C., Noy, A., Goy, A. & Yahalom, J. (2004) Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease. Blood, 104, 3483-3489.
22. Zinzani, P.L., Stefoni, V., Tani, M., Fanti, S., Musuraca, G., Castellucci, P., Marchi, E., Fina, M., Ambrosini, V., Pellegrini, C., Alinari, L., Derenzini, E., Montini, G., Broccoli, A., Bacci, F., Pileri, S. & Baccarani, M. (2009) Role of [18F]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma. Journal of Clinical Oncology, 27, 1781-1787.